<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-306
Date of Submission: 2025-08-12

This report was submitted by a Patient from Parks and Sons Medical Center concerning patient ANON-PX-4089. The subject is an adult male with a significant medical history including hypertension, osteoarthritis, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Subcutaneous route at a dosage of 330mg, initiated on 2025-07-20 for Gastroesophageal reflux disease and discontinued on 2025-08-09; Atorvastatin (Statin) administered via the Intravenous route at a dosage of 441mg, initiated on 2025-07-20 for Hypercholesterolemia and discontinued on 2025-08-09.

On approximately 2025-07-31, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Dizziness. The Headache was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed local and advised no. The current patient status regarding this symptom is 'Not Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Chance draw yeah open. Score give give new while. Win director place.</data>
report_id: ADR-2025-306
report_date: '2025-08-12'
patient_details:
  patient_id: ANON-PX-4089
  gender: Male
  relevant_history:
  - hypertension
  - osteoarthritis
  - migraines
suspected_drugs:
- drug_name: Omeprazole
  dosage: 330mg
  route_of_administration: Subcutaneous
  start_date: '2025-07-20'
  indication_for_use: Gastroesophageal reflux disease
  drug_class: Proton-pump inhibitor
  end_date: '2025-08-09'
- drug_name: Atorvastatin
  dosage: 441mg
  route_of_administration: Intravenous
  start_date: '2025-07-20'
  indication_for_use: Hypercholesterolemia
  drug_class: Statin
  end_date: '2025-08-09'
adverse_reactions:
- symptom_name: Headache
  onset_date: '2025-07-31'
  severity: Severe
  outcome: Fatal
  intervention_required: false
- symptom_name: Dizziness
  onset_date: '2025-07-31'
  severity: Mild
  outcome: Not Recovered
  intervention_required: true
  intervention_details: Prescribed local and advised no.
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Rechallenge not performed
  naranjo_score: 6
reporting_facility: Parks and Sons Medical Center
reporter_type: Patient
notes: Chance draw yeah open. Score give give new while. Win director place.
